Bailard’s Ionis Pharmaceuticals IONS Stock Holding History

Bailard’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,900	Closed	-$353K	–	569
2019 Q3	$353K	Hold	5,900	–	–	0.02%	365
2019 Q2	$379K	Buy	5,900 +100	+2%	+$7.07K	0.02%	356
2019 Q1	$471K	Hold	5,800	–	–	0.03%	307
2018 Q4	$314K	Hold	5,800	–	–	0.02%	411
2018 Q3	$299K	Hold	5,800	–	–	0.02%	469
2018 Q2	$242K	Hold	5,800	–	–	0.01%	475
2018 Q1	$256K	Hold	5,800	–	–	0.02%	432
2017 Q4	$292K	Buy	+5,800	New	+$318K	0.02%	377

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bailard's IONS Position: Q4 2019 in Review

Bailard sold out of Ionis Pharmaceuticals (IONS) in Q4 2019, closing a stake of 5,900 shares — an estimated $353K sold.

Bailard first reported a position in IONS in Q4 2017 and held it in 8 quarters. The position peaked at $471K in Q1 2019. 390 funds tracked by Wall St. Rank hold IONS as of Q4 2019.

Bailard reported no remaining Ionis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Bailard sold 5,900 Ionis Pharmaceuticals shares in Q4 2019, an estimated $353K.
Bailard first reported a position in Ionis Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Bailard's Ionis Pharmaceuticals position peaked at $471K in Q1 2019.
390 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2019.

Based on Bailard's 13F filing for Q4 2019, filed 31 Jan 2020.